ZFN-Mediated SERPINA1 Gene Editing (Sangamo Therapeutics/Albert Einstein College of Medicine/Washington University School of Medicine/University of Pittsburgh)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameZFN-Mediated SERPINA1 Gene Editing (Sangamo Therapeutics/Albert Einstein College of Medicine/Washington University School of Medicine/University of Pittsburgh)
Drug Alias NameAAV-ZFN gene therapy (Sangamo Therapeutics/Albert Einstein College of Medicine/Washington University School of Medicine/University of Pittsburgh)zinc finger nuclease gene therapy (Sangamo Therapeutics/Albert Einstein College of Medicine/Washington University School of Medicine/University of Pittsburgh)SERPINA1 gene editing therapy (Sangamo Therapeutics/Albert Einstein College of Medicine/Washington University School of Medicine/University of Pittsburgh)
ClassificationBiologics
Mechanisms of ActionAlpha-1-antiproteinase stimulantsAlpha-1-antiproteinase modulators
TargetsAlpha-1-antiproteinase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWashington UniversitySangamo Therapeutics IncUniversity Of Pittsburgh +[4] 
Active IndicationsN/A
Inactive Indicationsalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A